Paraneoplastic Neurologic Syndromes: Approaches to Diagnosis and Treatment

 

 Buy Article Permissions and Reprints

ABSTRACT

There is increasing evidence that many paraneoplastic neurologic syndromes are immune-mediated. Because symptoms usually have an acute onset and precede the tumor diagnosis, the recognition of a neurologic disorder as a paraneoplastic syndrome is challenging. The poor response to treatment of many paraneoplastic neurologic syndromes has been attributed to the early, irreversible pathological changes involving the nervous system. This may account for the more frequent responses to therapy of some paraneoplastic neurologic syndromes affecting the peripheral nerves and neuromuscular junction compared with those that produce neuronal degeneration. This review focuses on the current therapeutic approaches to immune-mediated paraneoplastic neurologic syndromes, including prompt recognition of the disorder, detection and treatment of the associated tumor, and, in some disorders, immunosuppressive therapy.

REFERENCES

• 1 Dalmau J, Posner J B. Paraneoplastic syndromes affecting the nervous system.  Semin Oncol . 1997;  24 318-328
  PubMedGoogle Scholar
• 2 Rudnicki S A, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve and muscle.  Muscle Nerve . 2000;  23 1800-1818
  CrossrefPubMedGoogle Scholar
• 3 Rosenfeld M R, Dalmau J. The clinical spectrum and pathogenesis of paraneoplastic disorders of the central nervous system.  Hematol Oncol Clin North Am . 2001;  15 1109-1128
  CrossrefPubMedGoogle Scholar
• 4 Dropcho E J. Remote neurologic manifestations of cancer.  Neurol Clin . 2002;  20 85-122
  CrossrefPubMedGoogle Scholar
• 5 Dalmau J, Gultekin H S, Posner J B. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology.  Brain Pathol . 1999;  9 275-284
  PubMedGoogle Scholar
• 6 Albert M L, Darnell J C, Bender A, Francisco L M, Bhardwaj N, Darnell R B. Tumor-specific killer cells in paraneoplastic cerebellar degeneration.  Nat Med . 1998;  11 1321-1324
  PubMedGoogle Scholar
• 7 Tanaka M, Tanaka K, Shinozawa K, Idezuka J, Tsuji S. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody.  J Neurol Sci . 1998;  161 88-90
  CrossrefPubMedGoogle Scholar
• 8 Tanaka K, Tanaka M, Inuzuka T, Nakano R, Tsuji S. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody.  J Neurol Sci . 1999;  163 159-162
  CrossrefPubMedGoogle Scholar
• 9 Graus F, Dalmau J, Rene R. et al . Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.  J Clin Oncol . 1997;  15 2866-2872
  PubMedGoogle Scholar
• 10 Maddison P, Newsom-Davis J, Mills K R, Souhami R L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.  Lancet . 1999;  353 117-118
  PubMedGoogle Scholar
• 11 Rojas I, Graus F, Keime-Guibert F. et al . Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.  Neurology . 2000;  55 713-715
  PubMedGoogle Scholar
• 12 Vincent A. Antibodies to ion channels in paraneoplastic disorders.  Brain Pathol . 1999;  9 285-291
  PubMedGoogle Scholar
• 13 Tanaka K, Tanaka M, Onodera O, Igarashi S, Miyatake T, Tsuji S. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration.  J Neurol Sci . 1994;  127 153-158
  CrossrefPubMedGoogle Scholar
• 14 Tanaka K, Tanaka M, Igarashi S, Onodera O, Miyatake T, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody II: passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice.  Clin Neurol Neurosurg . 1995;  97 101-105
  CrossrefPubMedGoogle Scholar
• 15 Graus F, Illa I, Agusti M. et al . Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model.  J Neurol Sci . 1991;  106 82-87
  CrossrefPubMedGoogle Scholar
• 16 Sillevis Smitt A P, Manley G T, Posner J B. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice.  Neurology . 1995;  45 1873-1878
  CrossrefPubMedGoogle Scholar
• 17 Levin M C, Lee S M, Kalume F. et al . Autoimmunity due to molecular mimicry as a cause of neurological disease.  Nat Med . 2002;  8 509-513
  PubMedGoogle Scholar
• 18 Henson R A, Hoffman H L, Urich H. Encephalomyelitis with carcinoma.  Brain . 1965;  88 449-464
  CrossrefPubMedGoogle Scholar
• 19 Graus F, Ribalta T, Campo E. et al . Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis.  Neurology . 1990;  40 219-222
  PubMedGoogle Scholar
• 20 Jean W C, Dalmau J, Ho A, Posner J B. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis.  Neurology . 1994;  44 140-147
  CrossrefPubMedGoogle Scholar
• 21 Benyahia B, Liblau R, Merle-Béral H, Tourani J M, Dalmau J, Delattre J-Y. Cell-mediated auto-immunity in paraneoplastic neurologic syndromes with anti-Hu antibodies.  Ann Neurol . 1999;  45 162-167
  CrossrefPubMedGoogle Scholar
• 22 Albert M L, Austin L M, Darnell R B. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration.  Ann Neurol . 2000;  47 9-17
  CrossrefPubMedGoogle Scholar
• 23 Molinuevo J L, Graus F, Rene R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy.  Ann Neurol . 1998;  44 976-980
  CrossrefPubMedGoogle Scholar
• 24 Antoine J C, Honnorat J, Camdessanche J P. et al . Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy.  Ann Neurol . 2001;  49 214-221
  CrossrefPubMedGoogle Scholar
• 25 Dalmau J, Furneaux H M, Gralla R J, Kris M G, Posner J B. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer: a quantitative western blot analysis.  Ann Neurol . 1990;  27 544-552
  CrossrefPubMedGoogle Scholar
• 26 Vega F, Graus F, Chen Q M, Poisson M, Schuller E, Delattre J Y. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlation.  Neurology . 1994;  44 2145-2147
  PubMedGoogle Scholar
• 27 Antoine J C, Cinotti L, Tilikete C. et al . [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies.  Ann Neurol . 2000;  48 105-108
  CrossrefPubMedGoogle Scholar
• 28 Rees J H, Hain S F, Johnson M R. et al . The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders.  Brain . 2001;  124 2223-2231
  CrossrefPubMedGoogle Scholar
• 29 Gultekin S H, Rosenfeld M R, Voltz R, Eichen J, Posner J B, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.  Brain . 2000;  123 1481-1494
  CrossrefPubMedGoogle Scholar
• 30 Rosenfeld M R, Eichen J G, Wade D F, Posner J B, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins.  Ann Neurol . 2001;  50 339-348
  CrossrefPubMedGoogle Scholar
• 31 Dalmau J, Graus F, Rosenblum M K, Posner J B. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients.  Medicine . 1992;  71 59-72
  CrossrefPubMedGoogle Scholar
• 32 Honnorat J, Antoine J C, Derrington E, Aguera M, Belin M F. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes.  J Neurol Neurosurg Psychiatry . 1996;  61 270-278
  PubMedGoogle Scholar
• 33 Yu Z, Kryzer T J, Griesmann G E, Kim K-K, Benarroch E E, Lennon V A. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.  Ann Neurol . 2001;  49 146-154
  CrossrefPubMedGoogle Scholar
• 34 Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre J Y. Limbic encephalitis and small cell lung cancer: clinical and immunological features.  Brain . 1997;  120 923-928
  CrossrefPubMedGoogle Scholar
• 35 Keime-Guibert F, Graus F, Broet P. et al . Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor.  Neurology . 1999;  53 1719-1723
  CrossrefPubMedGoogle Scholar
• 36 Graus F, Keime-Guibert F, Rene R. et al . Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.  Brain . 2001;  124 1138-1148
  CrossrefPubMedGoogle Scholar
• 37 Wainwright M S, Martin P L, Morse R P. et al . Human herpesvirus 6 limbic encephalitis after stem cell transplantation.  Ann Neurol . 2001;  50 612-619
  CrossrefPubMedGoogle Scholar
• 38 Peterson K, Rosenblum M K, Kotanides H, Posner J B. Paraneoplastic cerebellar degeneration I: a clinical analysis of 55 anti-Yo antibody-positive patients.  Neurology . 1992;  42 1931-1937
  CrossrefPubMedGoogle Scholar
• 39 Graus F, Dalmau J, Valldeoriola F. et al . Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease.  J Neuroimmunol . 1997;  74 55-61
  CrossrefPubMedGoogle Scholar
• 40 Blaes F, Strittmatter M, Merkelbach S. et al . Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders.  J Neurol . 1999;  246 299-303
  PubMedGoogle Scholar
• 41 Stark E, Wurster U, Patzold U, Sailer M, Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration.  Arch Neurol . 1995;  52 814-818
  CrossrefPubMedGoogle Scholar
• 42 David Y B, Warner E, Levitan M, Sutton D M, Malkin M G, Dalmau J O. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin: a case report.  Cancer . 1996;  78 2153-2156
  CrossrefPubMedGoogle Scholar
• 43 Cocconi G, Ceci G, Juvarra G. Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis: a case report.  Cancer . 1985;  56 2318-2320
  PubMedGoogle Scholar
• 44 Paone J F, Jeyasingham K. Remission of cerebellar dysfunction after pneumonectomy for bronchogenic carcinoma.  N Engl J Med . 1980;  302 156
  PubMedGoogle Scholar
• 45 Counsell C E, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin.  Neurology . 1994;  44 1184-1185
  PubMedGoogle Scholar
• 46 de la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor.  Arch Neurol . 1998;  55 405-408
  CrossrefPubMedGoogle Scholar
• 47 Keime-Guibert F, Graus F, Fleury A. et al . Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.  J Neurol Neurosurg Psychiatry . 2000;  68 479-482
  CrossrefPubMedGoogle Scholar
• 48 Graus F, Vega F, Delattre J Y. et al . Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies.  Neurology . 1992;  42 536-540
  CrossrefPubMedGoogle Scholar
• 49 Uchuya M, Graus F, Vega F, Reñé R, Delattre J Y. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies.  J Neurol Neurosurg Psychiatry . 1996;  60 388-392
  CrossrefPubMedGoogle Scholar
• 50 Russo C, Cohn S L, Petruzzi M J, de Alarcon A P. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group.  Med Pediatr Oncol . 1997;  28 284-288
  CrossrefPubMedGoogle Scholar
• 51 Yiu V W, Kovithavongs T, McGonigle L F, Ferreira P. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome.  Pediatr Neurol . 2001;  24 72-74
  CrossrefPubMedGoogle Scholar
• 52 Hammer M S, Larsen M B, Stack C V. Outcome of children with opsoclonus-myoclonus regardless of etiology.  Pediatr Neurol . 1995;  13 21-24
  CrossrefPubMedGoogle Scholar
• 53 Mitchell W G, Snodgrass S R. Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome.  J Child Neurol . 1990;  5 153-158
  PubMedGoogle Scholar
• 54 Koh P S, Raffensperger J G, Berry S. et al . Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma.  J Pediatr . 1994;  125 712-716
  PubMedGoogle Scholar
• 55 Anderson N E, Budde-Steffen C, Rosenblum M K. et al . Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome.  Medicine . 1988;  67 100-109
  PubMedGoogle Scholar
• 56 Luque F A, Furneaux H M, Ferziger R. et al . Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.  Ann Neurol . 1991;  29 241-251
  CrossrefPubMedGoogle Scholar
• 57 Bataller L, Graus F, Saiz A, Vilchez J. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.  Brain . 2001;  124 437-443
  CrossrefPubMedGoogle Scholar
• 58 Dropcho E J, Kline L B, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus.  Neurology . 1993;  43 207-211
  CrossrefPubMedGoogle Scholar
• 59 Cher L M, Hochberg F H, Teruya J. et al . Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption.  Cancer . 1995;  75 1678-1683
  CrossrefPubMedGoogle Scholar
• 60 Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome.  N Engl J Med . 1990;  322 1555-1560
  CrossrefPubMedGoogle Scholar
• 61 Folli F, Solimena M, Cofiell R. et al . Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer.  N Engl J Med . 1993;  328 546-551
  CrossrefPubMedGoogle Scholar
• 62 De Camilli P, Thomas A, Cofiell R. et al . The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer.  J Exp Med . 1993;  178 2219-2223
  CrossrefPubMedGoogle Scholar
• 63 Butler M H, Hayashi A, Ohkoshi N. et al . Autoimmunity to gephyrin in stiff-man syndrome.  Neuron . 2000;  26 307-312
  CrossrefPubMedGoogle Scholar
• 64 Antoine J C, Absi L, Honnorat J. et al . Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors.  Arch Neurol . 1999;  56 172-177
  CrossrefPubMedGoogle Scholar
• 65 Schmierer K, Valdueza J M, Bender A. et al . Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression.  Neurology . 1998;  51 250-252
  PubMedGoogle Scholar
• 66 Dalakas M C, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome.  N Engl J Med . 2001;  345 1870-1876
  CrossrefPubMedGoogle Scholar
• 67 Chalk C H, Windebank A J, Kimmel D W, McManis P G. The distinctive clinical features of paraneoplastic sensory neuronopathy.  Can J Neurol Sci . 1992;  19 346-351
  PubMedGoogle Scholar
• 68 Camdessanche J P, Antoine J C, Honnorat J. et al . Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiological study of 20 patients.  Brain . 2002;  125 166-175
  CrossrefPubMedGoogle Scholar
• 69 Oh S J, Dropcho E J, Claussen G C. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature.  Muscle Nerve . 1997;  20 1576-1582
  CrossrefPubMedGoogle Scholar
• 70 Oh S J. Paraneoplastic vasculitis of the peripheral nervous system.  Neurol Clin . 1997;  15 849-863
  CrossrefPubMedGoogle Scholar
• 71 Antoine J C, Mosnier J F, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies.  J Neurol Neurosurg Psychiatry . 1999;  67 7-14
  CrossrefPubMedGoogle Scholar
• 72 Tim R W, Massey J M, Sanders D B. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.  Neurology . 2000;  54 2176-2178
  PubMedGoogle Scholar
• 73 O'Neill J H, Murray N M, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases.  Brain . 1988;  111 577-596
  PubMedGoogle Scholar
• 74 Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?.  Neurology . 2001;  57 1579-1582
  PubMedGoogle Scholar
• 75 Hart I K, Maddison P, Newsom-Davis J, Vincent A, Mills K R. Phenotypic variants of autoimmune peripheral nerve hyperexcitability.  Brain . 2002;  125 1887-1895
  CrossrefPubMedGoogle Scholar